Form 4: Oramed CSO Miriam Kidron Reports Equity Awards

Oramed Pharmaceuticals Chief Scientific Officer Miriam Kidron reported the acquisition of Restricted Stock Units and Performance Stock Units.

Summary

• Miriam Kidron, Director and Chief Scientific Officer of Oramed Pharmaceuticals Inc. (ORMP), reported changes in beneficial ownership.
• Acquired 121,331 Restricted Stock Units (RSUs) on December 31, 2025, which vested in full on January 1, 2026.
• Acquired an additional 115,000 Restricted Stock Units (RSUs) on December 31, 2025, which will vest in quarterly installments over a three-year period starting January 1, 2026.
• Acquired 19,000 Performance Stock Units (PSUs) on December 31, 2025, which vest upon the achievement of either a specified stock price or applicable performance criteria.
• Following these transactions, Miriam Kidron beneficially owns 1,429,664 shares of Common Stock directly and 19,000 Performance Stock Units directly.

Sentiment

Score: 6

Explanation: The filing reports standard equity compensation awards to an executive, which is a neutral to slightly positive event as it aligns management's interests with shareholders. It does not contain information that would significantly alter the company's outlook or financial position.

Positives

• The acquisition of Restricted Stock Units and Performance Stock Units aligns the Chief Scientific Officer's interests with those of shareholders.
• Equity awards serve as a form of long-term incentive for executive performance and retention.

Risks

• The value of the Restricted Stock Units and Performance Stock Units is tied to the future performance of Oramed's common stock, exposing the recipient to market risk.
• Performance Stock Units are contingent on specific price or performance criteria, meaning they may not fully vest if conditions are not met.

Future Outlook

The filing indicates future vesting schedules for equity awards, with RSUs vesting quarterly over three years starting January 1, 2026, and PSUs vesting upon specific performance or price achievements.

Industry Context

NA

Stakeholder Impact

• Shareholders: Potential future dilution upon conversion of RSUs and PSUs into common stock, balanced by increased alignment of executive incentives with shareholder value.
• Employees (specifically Miriam Kidron): Receipt of significant equity compensation, providing long-term financial incentives tied to company performance.

Next Steps

• Continued vesting of 115,000 RSUs in quarterly installments over a three-year period starting January 1, 2026.
• Achievement of specified stock price or performance criteria for the 19,000 PSUs to vest.

Key Dates

Keywords

Oramed Pharmaceuticals, ORMP, Miriam Kidron, Form 4, Insider Transaction, Restricted Stock Units, Performance Stock Units, Equity Compensation, Executive Compensation